SpaceX reveals new target date for private crewed launch to ISS
SpaceX, partnering with NASA and Axiom Space, is aiming to blast a four-person crew to orbit at 3:42 a.m. ET on Sunday, June 22.
The private Ax-4 mission was supposed to launch to the International Space Station (ISS) from Florida's Kennedy Space Center on June 10, but inclement weather in the ascent corridor forced the mission team to call off the effort. A plan to launch 24 hours later was also ditched following the discovery of a liquid oxygen leak on the rocket.
Recommended Videos
NASA has also been monitoring an air leak in the Russian Zvezda service module at the space station, an additional situation that prompted NASA, in coordination with its Russian counterpart Roscosmos, to delay the Ax-4 launch for safety reasons while they worked out what to do. Following repairs, pressure in the affected area stabilized, and NASA was able to announce a new target launch date.
After patiently waiting in isolation at the Kennedy Space Center, the four crewmembers are now setting their sights on this Sunday, hoping that their long-awaited orbital adventure can finally begin.
'The change in a targeted launch date provides NASA time to continue evaluating space station operations after recent repair work in the aft (back) most segment of the International Space Station's Zvezda service module,' Axiom Space said in a release.
Peggy Whitson, a former NASA astronaut and now director of human spaceflight at Axiom Space, will command the commercial mission. Flying with her in a SpaceX Crew Dragon capsule will be individuals from India, Poland, and Hungary, with each nation on the cusp of celebrating its first-ever mission to the space station.
The mission will last about two weeks, with the four members living and working alongside the current ISS crew.
Interested in watching SpaceX's first crewed launch since Crew-10's flight in March? Digital Trends has everything you need to know.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
PODD Drug Delivery Conference Announces 2025 Keynotes
The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 keynotes NEW YORK, June 18, 2025 /PRNewswire/ -- Today, PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA. "In presenting a strategic-level program for R&D scientists and business development professionals, the PODD Conference is committed to securing keynotes who demonstrate excellence in science," said Andrew Goldstein, Senior Conference Producer for the PODD Conference. The PODD 2025 keynotes include: MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will return as the Annual Keynote to discuss the state of innovation in the drug delivery industry. Dr Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor who drove the development of GLP-1 drugs for obesity will present on the liraglutide and semaglutide story, her approach to scientific development and where drug delivery intersects with her R&D work. Patient Keynote Jimi Olaghere will share his journey as a patient with sickle cell disease before and after receiving CASGEVY, a CRISPR-based therapy, and his mission to make these therapies more accessible for patients globally. Dr Mansoor Amiji, University Distinguished Professor, Northwestern University, will join the PODD Conference as the Endogenous Delivery Zeitgeist. Dr Amiji will present on endogenous targeted delivery strategies to overcome biological barriers and improve efficacy and safety. The PODD speaking faculty includes over 100 executives from both the drug development and delivery industries with over 125 session choices including a full afternoon of drug delivery presentations from established to start-up companies. To learn more about the event, visit About the PODD: Partnership Opportunities in Drug Delivery ConferencePharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals, and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations. About the Conference ForumThe Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, promoting the exchange of ideas and solutions among peers, and providing high-quality networking. Learn more about the Conference Forum at For media inquiries, contact:Bre Bugbee-Barrettbre@ View original content: SOURCE Partnership Opportunities in Drug Delivery (PODD)
Associated Press
an hour ago
- Associated Press
Moolec Science Secures Core U.S. Patent for Piggy Sooy(TM), Soybean Expressing Up to 30% of Animal Protein
WARWICK, GB / ACCESS Newswire / June 18, 2025 / Moolec Science Limited a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC; 'The Company"; 'Moolec'), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its proprietary groundbreaking Piggy Sooy™ technology - soybean plant engineered to express high levels of porcine hemeproteins in their Science Logo Piggy Sooy™ is the first patented soybean technology designed to produce high levels of porcine hemeproteins directly in the seeds. The U.S. patent covers the plants and seeds, the method used to develop them, and food compositions derived from this breakthrough innovation. In April 2024, the USDA-APHIS confirmed that Piggy Sooy™ does not present plant pest risk difference from conventional soybeans, determining it is not subject to regulation under 7 CFR part 340 - a key regulatory milestone toward commercialization. Moolec's Chief Science Officer, Amit Dhingra, stated: 'Initial field trials demonstrated promising production yield, with over 20% animal protein content in the total soluble protein fraction. Furthermore, the deployment of Piggy Sooy™ technology presents compelling environmental benefits when compared to traditional agricultural and meat production practices. One acre of Piggy Sooy™ has the potential capacity to produce the same amount of protein as approximately 10 pigs, using ~35x less land, generating ~8x less water footprint and ~60x less CO2 emissions. These multifaceted benefits make Piggy Sooy™ a game-changer in sustainable protein production.' This patent provides Moolec with exclusive commercial rights to Piggy Sooy™ technology in the U.S. until 2042, significantly strengthening the Company's intellectual property portfolio. This is the first in a series of over fifteen patent applications filed globally aimed at protecting Moolec's Molecular Farming innovations. 'Our experience has taught us that long-term success in biotechnology is built on securing robust, enforceable intellectual property. This patent validates Moolec's scientific leadership in Molecular Farming and protects a technology with unprecedented levels of animal protein expression in plants. It's not only a recognition of our innovation, but a vital asset that allows us to advance confidently toward commercialization and build a differentiated position in our food and feed ingredients business,' said Alejandro Antalich, CEO of Moolec Science. Contact InformationPress & Media Investor Relations SOURCE: Moolec Science press release
Associated Press
an hour ago
- Associated Press
Social and Economic Factors Explain Why Black Patients Lose Less Weight After Bariatric Surgery than Other Groups
NEW YORK, June 18, 2025 /PRNewswire/ -- Weight loss surgery has long been an effective treatment for the more than 40 percent of the American adults struggling with obesity. While previous studies show that Black patients lose less weight overall following bariatric surgery compared to other racial groups, less attention has been paid to the relationships between economic and social factors that may help explain differences in weight loss. New research led by NYU Langone Grossman School of Medicine found that Black patients who underwent sleeve gastrectomy, the most common weight loss surgery, between 2017 and 2020 lost 6.2 percent less weight than their White counterparts, and 4.9 percent less than Hispanic patients, after one year. However, further analyses found that a lot more complexity and interplay between non-biological factors than previously known appear to impact weight loss surgery incomes. Published online in the journal Obesity, this is the first study to investigate the relationship between a variety of economic and social factors that include income, sleep disturbances and stress, and weight loss differences among racial groups, the study authors said. 'Our findings identified variations in bariatric surgery outcomes so that we can address them and, when appropriate, offer patients individualized support that can help promote the best possible outcomes,' said Melanie Jay, MD, professor in the Departments of Medicine and Population Health at NYU Langone Health, and senior author of the study. How the Study was Conducted Study participants who self-identified as either Non-Hispanic Black, Hispanic, or Non-Hispanic White were recruited from NYU Langone Health Tisch Hospital and NYC Health + Hospital Bellevue Hospital from June 2017 to March 2020. The researchers measured patients' total weight loss, waist circumference, body composition, hormones, and blood glucose levels—following up with them at multiple intervals through in-clinic visits and questionnaires over two years. Analyzing data from 297 patients, the investigators found that after surgery, non-Hispanic Black patients lost less total weight at nearly every follow-up interval compared to their Hispanic and White counterparts. Black patients also consistently reported higher sleep disturbance, perceived stress, and experiences of discrimination. In contrast, no significant differences in total weight loss were observed between Hispanic and White patients. White patients also were found to have better long-term blood glucose control than both Black and Hispanic patients after follow-up. 'These varied associations highlight how different lived experiences and self-perceptions across racial and ethnic groups can influence surgical outcomes,' said Sally M. Vanegas, PhD, research assistant professor in the Department of Medicine and lead study author. 'Additional research is needed to better understand how a broader range of socioeconomic factors may shape these outcomes.' José O. Alemán, MD, PhD, an endocrinologist at NYU Langone and co-senior author of the study said he and his colleagues will continue analyzing data from the study participants to explore additional biological factors that may influence weight loss surgery outcomes, including changes in gene expression and the microbiome. 'As a clinical community, we have to be honest that these differences exist, as well as reinforce the importance of adopting a holistic approach to care.' In addition to Jay, Alemán and Vanegas, additional collaborators from NYU Langone Health include Silvia Curado, PhD, Boyan Zhou, PhD, Ericka N. Merriwether, PhD, Nicholas Illenberger, PhD, Evelyn Armijos, Ann Marie Schmidt, MD, Christine Ren-Fielding, Manish Parikh, MD, and Brian Elbel, PhD. The study was provided with institutional support from NYU Langone Health and obtained donor support through the J. Ira and Nicki Harris Family Foundation, an AHA Ignition Center Grant (17SFRN33590133), and the Clinical and Translational Science Institute (CTSI), which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001445. SMV was in part supported by 2T32HL098129 from the National Heart, Lung and Blood Institute. JOA was in part supported by K08DK117064 from the National Institute of Diabetes and Digestive and Kidney Diseases and the Doris Duke Foundation. MJ was in part supported by the National Heart, Lung and Blood Institute (K24 HL165161-01A1). About NYU Langone Health NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise. Media Inquiries: Sasha Walek 646-501-3873 [email protected] View original content to download multimedia: SOURCE NYU Langone Health System
